0001062993-23-006328.txt : 20230308
0001062993-23-006328.hdr.sgml : 20230308
20230308200408
ACCESSION NUMBER: 0001062993-23-006328
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230306
FILED AS OF DATE: 20230308
DATE AS OF CHANGE: 20230308
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Taylor Stacy L
CENTRAL INDEX KEY: 0001799081
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38957
FILM NUMBER: 23717817
MAIL ADDRESS:
STREET 1: C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
STREET 2: 1551 EASTLAKE AVENUE E SUITE 200
CITY: SEATTLE
STATE: WA
ZIP: 98102
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Adaptive Biotechnologies Corp
CENTRAL INDEX KEY: 0001478320
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 270907024
STATE OF INCORPORATION: WA
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 1165 EASTLAKE AVE E
CITY: SEATTLE
STATE: WA
ZIP: 98109
BUSINESS PHONE: 206-659-0067
MAIL ADDRESS:
STREET 1: 1165 EASTLAKE AVE E
CITY: SEATTLE
STATE: WA
ZIP: 98109
FORMER COMPANY:
FORMER CONFORMED NAME: Adaptive TCR Corp
DATE OF NAME CHANGE: 20091209
4
1
form4.xml
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
X0306
4
2023-03-06
0001478320
Adaptive Biotechnologies Corp
ADPT
0001799081
Taylor Stacy L
C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION
1165 EASTLAKE AVENUE EAST
SEATTLE
WA
98109
0
1
0
0
SVP and General Counsel
Common Stock
2023-03-06
4
A
0
85697
0
A
158556
D
Common Stock
2023-03-06
4
S
0
5491
8.57
D
153065
D
Common Stock
2023-03-07
4
S
0
13387
8.60
D
139678
D
Stock Option (right to buy)
8.46
2023-03-06
4
A
0
128599
0
A
2033-03-06
Common Stock
128599
128599
D
This transaction represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs. This sale is mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the Reporting Person.
The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 16, 2022.
The price reported for this transaction is a weighted-average price. The shares were sold in multiple transactions ranging from $8.30 to $8.89, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.
The options vest with respect to 1/4 of such shares on March 4, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.
/s/ Stacy L Taylor
2023-03-08